Beyond Vancomycin: The Tail of the Lipoglycopeptides

Clinical Therapeutics

Volumn 37, Issue 12, 2015, Pages 2619-2636

  Klinker, Kenneth P ^a   Borgert, Samuel J ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

acute bacterial skin and skin structure infections; dalbavancin; oritavancin; telavancin

Indexed keywords

DALBAVANCIN; GLYCOPEPTIDE; ORITAVANCIN; TELAVANCIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; LIPOPEPTIDE; TEICOPLANIN;

ACUTE KIDNEY FAILURE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; BACTERIAL SKIN DISEASE; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM PERFRINGENS; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE INFECTION; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; REVIEW; STREPTOCOCCUS PNEUMONIAE; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIOLOGY;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LIPOPEPTIDES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84950246550     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.11.007     Document Type: Review

References (98)

1. Centers for Disease Control. Antibiotic resistance threats in the United States, 2013. (2013). http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed May 15, 2015.
2. M.P. Jevons 'Celbenin'-resistant staphylococci Br Med J 1 1961 124 125
3. S. Tsiodras, H.S. Gold, G. Sakoulas, and et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus Lancet 358 2001 207 208
4. A. Mangili, I. Bica, D. Snydman, and et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 40 2005 1058 1060
5. R.C. Moellering MRSA: the first half century J Antimicrob Chemother 67 2012 4 11
6. T.P. Lodise, and P.S. McKinnon Burden of methicillin-resistant Staphylococcus aureus: Focus on clinical and economic outcomes Pharmacother J Hum Pharmacol Drug Ther 27 2007 1001 1012
7. E. Klein, D.L. Smith, and R. Laxminarayan Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005 Emerg Infect Dis 13 2007 1840 1846
8. R. Dantes, Y. Mu, R. Belflower, and et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011 JAMA Intern Med 173 21 2013 1970 1978
9. D.M. Sievert, P. Ricks, J.R. Edwards, and et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the national healthcare safety network at the Centers for Disease Control and Prevention, 2009-2010 Infect Control Hosp Epidemiol 34 2013 1 14
10. G.T. Ray, J.A. Suaya, and R. Baxter Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a US population: a retrospective population-based study BMC Infect Dis 13 2013 252
11. M.E. Stryjewski, D.R. Graham, S.E. Wilson, and et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms Clin Infect Dis 46 2008 1683 1693
12. H.W. Boucher, M. Wilcox, G.H. Talbot, and et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection N Engl J Med 370 2014 2169 2179
13. G.R. Corey, S. Good, H. Jiang, and et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: The SOLO II noninferiority study Clin Infect Dis 60 2015 254 262
14. C. Liu, A. Bayer, S.E. Cosgrove, and et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis 52 2011 e18 e55
15. M. Rybak, B. Lomaestro, J.C. Rotschafer, and et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 2009 82 98
16. R. Kullar, S.L. Davis, D.P. Levine, and et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines Pharmacother J Hum Pharmacol Drug Ther 31 2011 441 448
17. G. Sakoulas, P.A. Moise-Broder, J. Schentag, and et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia J Clin Microbiol 42 2004 2398 2402
18. L.K. Hidayat, D.I. Hsu, R. Quist, and et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity Arch Intern Med 166 2006 2138 2144
19. N. Holmes, S. Tong, J. Davis, and et al. Treatment of methicillin-resistant Staphylococcus aureus: Vancomycin and beyond Semin Respir Crit Care Med 36 2015 17 30
20. M.S. Butler, K.A. Hansford, M.A. Blaskovich, and et al. Glycopeptide antibiotics: Back to the future J Antibiot (Tokyo) 67 2014 631 644
21. T.P. Lodise, N. Patel, B.M. Lomaestro, and et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients Clin Infect Dis 49 2009 507 514
22. S.J. Van Hal, D.L. Paterson, and T.P. Lodise Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter Antimicrob Agents Chemother 57 2013 734 744
23. G.G. Zhanel, D. Calic, S. Zelenitsky, and et al. New lipoglycopeptides A comparative review of dalbavancin, oritavancin and telavancin Drugs 70 2010 859 886
24. M.R. Leadbetter, S.M. Adams, B. Bazzini, and et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424) J Antibiot (Tokyo) 57 2004 326 336
25. L.D. Saravolatz, G.E. Stein, and L.B. Johnson Telavancin: a novel lipoglycopeptide Clin Infect Dis 49 2009 1908 1914
26. M. Billeter, M.J. Zervos, A.Y. Chen, and et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic Clin Infect Dis 46 2008 577 583
27. A. Malabarba, and B.P. Goldstein Origin, structure, and activity in vitro and in vivo of dalbavancin J Antimicrob Chemother 55 2005 ii15 ii20
28. G.G. Zhanel, F. Schweizer, and J.A. Karlowsky Oritavancin: mechanism of action Clin Infect Dis 54 2012 S214 S219
29. N.E. Allen, and T.I. Nicas Mechanism of action of oritavancin and related glycopeptide antibiotics FEMS Microbiol Rev 26 2003 511 532
30. S.J. Kim, L. Cegelski, D. Steuber, and et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus J Mol Biol 377 2008 281 293
31. S.N. Leonard, and M.J. Rybak Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections Pharmacother J Hum Pharmacol. Drug Ther 28 2008 458 468
32. R.E. Mendes, D.J. Farrel, H.S. Sader, and et al. Oritavancin microbiologic features and activity results from the surveillance program in the United States Clin Infect Dis 54 2012 S203 S213
33. C. Vidaillac, J. Parra-Ruiz, and M.J. Rybak In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin Diagn Microbiol Infect Dis 71 2011 470 473
34. R.E. Mendes, D.J. Farrel, H.S. Sader, and et al. Update of the telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2013), when applying the revised susceptibility testing method Diagn Microbiol Infect Dis 81 2015 275 279
35. th Annual meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington DC.
36. E.J. Goldstein, D.M. Citron, C.V. Merriam, and et al. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp Antimicrob Agents Chemother 48 2004 2149 2152
37. D.M. Citron, Y.Y. Kwok, and M.D. Appleman In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic gram-positive cocci Anaerobe 11 2005 93 95
38. th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. September, 2014; Washington DC.
39. D.M. Citron, K.L. Tyrrell, and E.J. Goldstein Comparative in vitro activities of dalbavancin and seven comparator agents against 41 staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains Diagn Microbiol Infect Dis 79 2014 438 440
40. E.J. Goldstein, D.M. Citron, C.V. Merriam, and et al. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria Antimicrob Agents Chemother 47 2003 1968 1971
41. R.N. Jones, H.S. Sader, R.K. Flamm, and et al. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011) Diagn Microbiol Infect Dis 75 2013 304 307
42. th European Congress of Clinical Microbiology and Infectious Diseases Copenhagen, Denmark; 2015
43. F.F. Arhin, I. Sarmiento, A. Belley, and et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: Implications for susceptibility testing Antimicrob Agents Chemother 52 2008 1597 1603
44. Vibativ [package insert] 2014 Theravance Biopharma Antiobiotics, Inc San Francisco, CA
45. R.E. Mendes, D.J. Farrell, H.S. Sader, and et al. Baseline activity of telavancin against gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method Antimicrob Agents Chemother 59 2015 702 706
46. C.A. Arias, R.E. Mendes, M.G. Stilwell, and et al. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections Clin Infect Dis 54 2012 S233 S238
47. R.E. Mendes, L.N. Woosley, D.J. Farrell, and et al. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010 Antimicrob Agents Chemother 56 2012 1639 1642
48. P. Courvalin Vancomycin resistance in gram-positive cocci Clin Infect Dis 42 2006 S25 S34
49. S. Gardete, and A. Tomasz Mechanisms of vancomycin resistance in Staphylococcus aureus J Clin Invest 124 2014 2836 2840
50. th Annual meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy. September 27-30, 2006; San Francisco, CA.
51. K. Kosowska-Shick, C. Clark, G.A. Pankuch, and et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies Antimicrob Agents Chemother 53 2009 4217 4224
52. B.P. Goldstein, D.C. Draghi, D.J. Sheehan, and et al. Bactericidal activity and resistance development profiling of dalbavancin Antimicrob Agents Chemother 51 2007 1150 1154
53. FDA. FDA Briefing Document for NDA 206334: Oritavancin diphosphate. Microbiology and Virology review. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/206334Orig1s000MicroR.pdf. accessed May 31, 2015
54. R.N. Jones, D.J. Farrell, R.K. Flamm, and et al. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin Diagn Microbiol Infect Dis 82 2015 73 77
55. R.N. Jones, J.D. Turndige, G. Moeck, and et al. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide Antimicrob Agents Chemother 59 2015 2405 2409
56. R.E. Mendes, D.J. Farrell, R.K. Flamm, and et al. Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin J Clin Microbiol 53 8 2015 2727 2730
57. J.P. Shaw, J. Seroogy, K. Kaniga, and et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects Antimicrob Agents Chemother 49 2005 195 201
58. S.L. Wong, S.L. Barriere, M.M. Kitt, and et al. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects J Antimicrob Chemother 62 2008 780 783
59. T.P. Lodise, J.M. Butterfield, S.S. Hedge, and et al. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function Antimicrob Agents Chemother 56 2012 2062 2066
60. C.M. Rubino, S.M. Bhavnani, G. Moeck, and et al. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials Antimicrob Agents Chemother 59 2015 3365 3372
61. E. Samara, J.P. Shaw, S.L. Barriere, and et al. Population pharmacokinetics of telavancin in healthy subjects and patients with infections Antimicrob Agents Chemother 56 2012 2067 2073
62. th Annual Meeting of the European Congress of Clinical Microbiology and Infectious Disease. 2005; Copenhagen, Denmark.
63. J.H. Patel, M.D. Churchwell, J.D. Seroogy, and et al. Telavancin and hydroxy propyl-β-cyclodextrin clearance during continuous renal replacement therapy: An in vitro study Int J Artif Organs 32 2009 745 751
64. M.R. Goldberg, S.L. Wong, J.P. Shaw, and et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin Pharmacother J Hum Pharmacol Drug Ther 30 2010 35 42
65. H.K. Sun, K. Duchin, C.H. Nightingale, and et al. Tissue penetration of telavancin after intravenous administration in healthy subjects Antimicrob Agents Chemother 50 2006 788 790
66. M.H. Gotfried, J.P. Shaw, B.M. Benton, and et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics Antimicrob Agents Chemother 52 2008 92 97
67. L.D. Saravolatz, and G.E. Stein Oritavancin: A long-half-life lipoglycopeptide Clin Infect Dis 61 4 2015 627 632
68. A. Kumar, H.J. Mann, M. Keshtgarpour, and et al. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers Int J Artif Organs 34 2011 1067 1074
69. B. Baquir, S. Lemaire, F. Van Bambeke, and et al. Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin Clin Infect Dis 54 2012 S229 S232
70. G.J. Fetterly, C.M. Ong, S.M. Bhavnani, and et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose Antimicrob Agents Chemother 49 2005 148 152
71. C. Cabellos, A. Fernandez, J.M. Maiques, and et al. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis Antimicrob Agents Chemother 47 2003 1907 1911
72. P.G. Ambrose, G.L. Drusano, and W.A. Craig In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans Clin Infect Dis 54 2012 S220 S228
73. L.M. Dunbar, J. Milata, T. McClure, and et al. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial Antimicrob Agents Chemother 55 2011 3476 3484
74. M. Buckwalter, and J.A. Dowell Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide J Clin Pharmacol 45 2005 1279 1287
75. T. Marbury, J.A. Dowell, E. Seltzer, and et al. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment J Clin Pharmacol 49 2009 465 476
76. E.G. Solon, J.A. Dowell, J. Lee, and et al. Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits Antimicrob Agents Chemother 51 2007 3008 3010
77. Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother. 2005;55:ii31-ii35.
78. M.W. Dunne, S. Puttagunta, C.R. Sprenger, and et al. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue Antimicrob Agents Chemother 59 2015 1849 1855
79. D. Andes, and W.A. Craig In vivo pharmacodynamic activity of the glycopeptide dalbavancin Antimicrob Agents Chemother 51 2007 1633 1642
80. FDA. FDA Briefing Document, NDA 021833. Advisory committee meeting: March 31, 2014. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/ucm390788.htm; accessed May 31, 2015.
81. K.A. Polyzos, M.N. Mavros, K.Z. Vardaka, and et al. Efficacy and safety of telavancin in clinical trials: A systematic review and meta-analysis PLoS ONE 7 2012 e41870
82. G.R. Corey, and M.E. Stryjewski New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: Do not let the perfect be the enemy of the good Clin Infect Dis 52 2011 S469 S476
83. E. Rubinstein, T. Lalani, G.R. Corey, and et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens Clin Infect Dis 52 2011 31 40
84. R.G. Corey, M.H. Kollef, E. Rubinstein, and et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival Antimicrob Agents Chemother 58 2014 2030 2037
85. M.K. Lacy, M.E. Stryjewski, W. Wang, and et al. Telavancin hospital-acquired pneumonia trials: Impact of gram-negative infections and inadequate gram-negative coverage on clinical efficacy and all-cause mortality Clin Infect Dis 61 suppl2 2015 S87 S93
86. M.E. Styjewski, A. Lentnek, W. O'Riordan, and et al. A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: The ASSURE study BMC Infect Dis 14 2014 289
87. G.R. Corey, H. Kabler, P. Mehra, and et al. Single-dose oritavancin in the treatment of acute bacterial skin infections N Engl J Med 370 2014 2180 2190
88. De la Pena A, Chien J, Geiser J, et al. Microbiological outcomes and pharmacokinetics of oritavancin in patients with Gram-positive bacteremia. Poster presented at: The 12th European Congress of Clinical Microbiology and Infectious Diseases. Milan, Italy; 2002
89. Loutit J, O'Riordan W, San Juan J, et al. Phase 2 trial comparing four regimens of oritavancin vs. comparator in the treatment of patients with S. aureus bacteremia. Poster presented at: The 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague/Czech Republic; 2004
90. J. Crandon, and D.P. Nicolau Oritavancin: a potential weapon in the battle against serious gram-positive pathogens Future Microbiol 3 3 2008 251 260
91. E. Seltzer, M.B. Dorr, B.P. Goldstein, and et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections Clin Infect Dis 37 2003 1298 1303
92. Dunne MW, Puttagunta S, Giordano P, et al. Single dose treatment with dalbavancin for acute bacterial skin and skin structure infection. Poster presented at: Infectious Diseases Week (IDWeek); San Diego, CA; 2015
93. I. Raad, R. Darouiche, J. Vazquez, and et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens Clin Infect Dis 40 2005 374 380
94. Orbactiv [package insert] 2014 The Medicines Company Parsippany, NJ
95. A. Kumar, and H.J. Mann Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration Am J Health Syst Pharm 67 2010 1640 1644
96. Dunne MW, Das AF, Puttagunat S. An analysis of the safety profile of dalbavancin from the phase 2/3 clinical program [1334]. Poster presented at: Infectious Diseases Week; San Francisco, CA; 2013
97. Dalvance [package insert] 2014 Durata Therapeutics US Limited Chicago, IL
98. L.E. Jauregui, S. Babazadeh, E. Seltzer, and et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections Clin Infect Dis 41 2005 1407 1415